Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 19Neurofibroma, Plexiform 11Neurofibrosarcoma 3Sarcoma 1Peripheral Nervous System Diseases 1Pain 1Optic Nerve Glioma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Meningioma 1Lymphoma, Non-Hodgkin 1Heredodegenerative Disorders, Nervous System 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Bevacizumab 3contrast agent BR1 2Oncolytic Virotherapy 2vorasidenib 1pembrolizumab 1keyhole-limpet hemocyanin 1interferon gamma-1b 1Vaccines 1Temozolomide 1Stem Cell Transplantation 1Microbubbles 1Interleukin-12 1Interferon-gamma 1Immunotherapy 1Biopsy 1Antibodies, Monoclonal 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Nerve Tissue × AZD 6244 × CNS × Clear all
NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡